Changes in Beneficial Ownership · 4
Kiora Pharmaceuticals, Inc.
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1781295336.xml
Filing details
- Report period
- 2026-06-10
- Issuer
- KIORA PHARMACEUTICALS INC
- Issuer CIK
- 0001372514
- Trading symbol
- KPRX
Reporting owner 1
- Name
- Hollander David
- Reporting owner CIK
- 0001793796
- Relationship
- Director
- Address
- C/O KIORA PHARMACEUTICALS, INC., 169 SAXONY RD., SUITE 212, ENCINITAS, CA, 92024
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 2.63 | 2026-06-10 | A · Form 4 | 25,000 | A | 0 | 2027-06-10[F1] | 2036-06-10 | Common Stock | 25,000 | 25,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.↩ 1
Signature 1
- Signed
- /s/ Melissa Tosca, Attorney-in-Fact
- Date
- 2026-06-11
Company context
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for retinal disease. The Company targets critical pathways underlying retinal diseases using small molecules designed to slow, stop or restore vision loss. KIO-301 is being developed initially for retinitis pigmentosa, with potential expansion into choroideremia and Stargardt disease. KIO-104 is being developed for macular edema associated with retinal inflammation.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Regulation FD DisclosureOct 29, 2026
- SCHEDULE 13G - filed by Baselake Partners, LP regarding KIORA PHARMACEUTICALS INCSep 17, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 8, 2026
- Entry into a Material Definitive Agreement · Regulation FD DisclosureAug 19, 2026
- SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding KIORA PHARMACEUTICALS INCAug 14, 2026